(SRT3) Sartorius - Ratings and Ratios

Sartorius Aktiengesellschaft is a global supplier of innovative laboratory and bioprocess technologies, serving the life science research, biopharmaceutical manufacturing, cell and gene therapy, and applied industries. The companys comprehensive product portfolio includes bioreactors, fermenters, cell culture media, and various laboratory equipment and consumables, as well as services such as contract manufacturing, validation, and bioprocess consulting.

The companys products and services enable its customers to develop and manufacture biopharmaceuticals, vaccines, and other biotechnology products. Sartorius has a strong presence in the global market, with a diverse customer base across the life science and biopharmaceutical industries. With a history dating back to 1870, Sartorius has established itself as a trusted partner for its customers, providing high-quality products and expert services.

From a technical analysis perspective, Sartorius stock has shown a relatively stable trend in recent months, with a current price of 206.10 EUR. The stock is currently trading below its 20-day and 50-day simple moving averages (SMA20 and SMA50), indicating a potential short-term downtrend. However, the stocks average true range (ATR) is relatively low, suggesting that the price movement is not highly volatile. Based on the , a potential trading range for the stock could be between 200-220 EUR.

Fundamentally, Sartorius has a significant market presence, with a market capitalization of 13.637 billion EUR. The companys price-to-earnings (P/E) ratio is relatively high, at 160.00, indicating that investors have high expectations for the companys future growth. However, the forward P/E ratio is significantly lower, at 47.85, suggesting that the companys earnings are expected to grow substantially in the coming periods. With a return on equity (RoE) of 4.61, Sartorius is generating returns for its shareholders, albeit at a relatively modest level.

Based on the and , a forecast for Sartorius could be as follows: given the companys strong market presence and diversified product portfolio, it is likely to continue to grow its earnings in the coming periods. As the biopharmaceutical and life science industries continue to evolve, Sartorius is well-positioned to benefit from the increasing demand for its products and services. With a potential trading range of 200-220 EUR in the short term, the stock may be attractive to investors looking for a long-term growth opportunity. A potential price target for the stock could be around 250-260 EUR, representing a 20-25% increase from the current price.